A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18–64 Years of Age (Preliminary Results)

Background/Objectives: This study evaluated the Omicron LP.8.1 variant-adapted BNT162b2 mRNA vaccine (LP.8.1-adapted BNT162b2). Methods: This analysis is part of an ongoing phase 3 open-label study evaluating the immunogenicity, safety, and tolerability of LP.8.1-adapted BNT162b2. Reported here are...

Descrición completa

Detalles Bibliográficos

Principais autores:	Rucha Dadhe, Juleen Gayed, Muneeb Iqbal, Rohit Solan, Han Wu, Hua Ma, Xia Xu, Federico J. Mensa, Todd Belanger, David Cooper, Robin Mogg, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, Pirada Suphaphiphat Allen, Kayvon Modjarrad, Alejandra Gurtman, Kelly Lindert
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2026-04-01
Series:	Vaccines
Assuntos:	BNT162b2 COVID-19 Omicron SARS-CoV-2 vaccine variant-adapted
Acceso en liña:	https://www.mdpi.com/2076-393X/14/4/350
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!